

TRIOCHEM PRODUCTS LIMITED

MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS

Registered Office: 4th Floor, Sambava Chambers, Sir. P. M. Road,

Fort, Mumbai, Maharashtra, PIN: 400001. Telephone: 00 91 (22) 2266 3150

Fax: 00 91 (22) 2202 4657 E-mail: info@amphray.com

Website: www.triochemproducts.com Corporate Identity Number: L24249MH1972PLC015544



Ref No: TPL PP 200928 2020; 12th November 2020

To

BSE Limited

Corporate Relationship Department,

Phiroze Jeejeebhoy Towers, Dalal Street,

Fort, Mumbai: 400 001.

Security Code No. 512101 - ISIN No.: INE331E01013.

Dear Sir / Madam,

Sub: Submission of Unaudited Financial Results for the Quarter and Half Year ended 30th September 2020

We refer to our letter dated 4th November 2020 on the captioned subject.

Pursuant to Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, In this subject, we wish to inform you that the Board of Director of the Company at its meeting held today i.e. Thursday, 12th November, 2020 have inter-alia considered and approved the Unaudited Financial Results of the Company for the quarter and half year ended 30th September, 2020 duly reviewed by the Audit Committee along with Statement of Assets and Liabilities as at September 30, 2020 and Cash Flow Statement for the half year ended September 30, 2020.

The said financial results, duly signed by the Director & CEO of the company along with the statutory auditor's report are enclosed for your perusal and records.

Also, informed that the audited financial results in prescribed format will be published in "Free Press Journal" and "Navshakti" newspaper, as required. Please take the same in you record.

Thanking you,

Yours faithfully,

For TRIOCHEM PRODUCTS LIMITED

9
RAMU S. DEORA
DIRECTOR & CEO
DIN: 00312369
Encl.: as above



TRIOCHEM PRODUCTS LIMITED

MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS

Registered Office: 4th Floor, Sambava Chambers, Sir. P. M. Road, Fort, Mumbai, Maharashtra,

PIN: 400001. Telephone: 00 91 (22) 2266 3150 Fax: 00 91 (22) 2202 4657

E-mail: info@amphray.com Website: www.triochemproducts.com

Corporate Identity Number: L24249MH1972PLC015544

**TRIOCHEM PRODUCTS LIMITED**

Registered Office : Sambava Chamber, 4th Floor, Sir P M Road, Fort, Mumbai - 400 001.

Website: www.triochemproducts.com

CIN : L24249MH1972PLC015544

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2020

(Rs in Lakh) Except EPS						
Sr. No.	Particulars	Quarter Ended			Half Year Ended	
		30-Sep-20 (Unaudited)	30-Jun-20 (Unaudited)	30-Sep-19 (Unaudited)	30-Sep-20 (Unaudited)	30-Sep-19 (Unaudited)
						31-Mar-20 (Audited)
1	Income					
	(a) Revenue from Operations	225.86	-	261.76	225.86	314.36
	(b) Other Income	4.38	1.30	0.16	5.68	0.32
	Total Income From Operations	230.24	1.30	261.92	231.54	314.68
	Expenses					
	(a) Cost of Materials Consumed	226.06	418.48	-	644.54	-
	(b) Purchase of stock in trade	-	-	-	-	-
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(47.76)	(424.31)	166.65	(472.07)	202.55
	(d) Employees Benefit Expenses	16.89	16.89	19.36	33.78	34.88
	(e) Finance Costs	4.97	2.09	2.67	7.06	7.83
	(f) Depreciation and Amortisation Expenses	3.46	3.42	4.20	6.88	8.36
	(g) Other Expenditure	33.79	20.04	26.68	53.83	57.61
	Total expenses	237.41	36.61	219.56	274.02	311.23
3	Profit before exceptional items and tax	(7.16)	(35.31)	42.36	(42.47)	3.45
4	Exceptional items	-	-	-	-	-
5	Profit/ (Loss) before tax	(7.16)	(35.31)	42.36	(42.47)	3.45
6	Tax Expense					
	(a) Current tax	(0.00)	0.02	2.29	0.02	2.29
	(b) Deferred tax	(1.73)	(8.83)	7.27	(10.56)	(3.51)
	Total tax expenses	(1.73)	(8.81)	9.56	(10.54)	(1.22)
7	Net Profit/ (Loss) for the period	(5.43)	(26.50)	32.80	(31.93)	4.67
8	Other Comprehensive Income (Net of Taxes)					
	(A)(i). Items that will be reclassified to profit or loss	-	-	-	-	-
	(ii). Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
	(B)(i). Item that will not be reclassified to profit or loss	(1.06)	0.11	(0.30)	(0.95)	(0.29)
	(ii). Income tax relating to items that will not be reclassified to profit or loss	0.27	(0.03)	0.09	0.24	0.08
	Total other Comprehensive Income (net of taxes)	(0.79)	0.09	(0.21)	(0.71)	(0.21)
9	Total Comprehensive Income for the period	(6.22)	(26.42)	32.59	(32.64)	4.46
10	Paid-up equity share capital (Face Value of ₹ 10/- per share)	24.50	24.50	24.50	24.50	24.50
11	Other equity as per Balance Sheet of previous accounting year					1,193.14
12	Earnings per equity share (EPS) (of Rs. 10/- each) (not annualised)					
	Basic / Diluted EPS (in Rs.)	(2.22)	(10.82)	13.39	(13.03)	1.91



Signature

TRIOCHEM PRODUCTS LIMITED

MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS

Registered Office: 4th Floor, Sambava Chambers, Sir. P. M. Road, Fort, Mumbai, Maharashtra,

PIN: 400001. Telephone: 00 91 (22) 2266 3150 Fax: 00 91 (22) 2202 4657

E-mail: info@amphray.com Website: www.triochemproducts.com

Corporate Identity Number: L24249MH1972PLC015544



STATEMENT OF ASSETS AND LIABILITIES AS AT 30TH SEPTEMBER, 2020			
	Particulars	As at 30-Sep-20 (Unaudited)	As at 31-Mar-20 (Audited)
A	ASSETS		
1	Non- Current Assets		
	(a) Property, plant and equipment	90.83	97.51
	(b) Capital work - in - progress	3.24	3.24
	(c) Investment property	7.92	8.11
	(d) Financial assets		
	(i) Other financial assets	7.32	7.32
	(e) Deferred tax assets (Net)	1.47	-
	(e) Other non current tax assets	-	7.26
	(f) Other non current assets	1.36	1.19
	Sub Total - Non- Current Assets	112.14	124.63
2	Current Assets		
	(a) Inventories	1,168.24	155.41
	(b) Financial Assets		
	(i) Trade receivable	15.29	1,239.89
	(ii) Cash and cash equivalents	84.54	55.31
	(iii) Other financial assets	0.33	0.59
	(c) Other tax assets (net)	22.00	-
	(c) Other current assets	146.51	85.85
	Sub Total - Current Assets	1,436.91	1,537.05
	TOTAL ASSETS	1,549.05	1,661.68
B	EQUITY AND LIABILITIES		
1	Equity		
	(a) Equity share capital	24.50	24.50
	(b) Other equity	1,160.50	1,193.14
	Sub Total - Shareholder's fund	1,185.00	1,217.64
2	Liabilities		
	(a) Non Current Liabilities		
	(a) Deferred tax liabilities (Net)	-	9.33
	(b) Current Liabilities		
	(a) Financial liabilities		
	(i) Borrowing	300.57	250.30
	(ii) Trade payables	36.22	74.01
	(b) Other financial liabilities	6.33	13.93
	(c) Other current liabilities	3.68	79.86
	(d) Provisions	9.68	9.05
	(e) Current tax liabilities (Net)	7.56	7.56
	Sub Total - Liabilities	364.05	444.04
	TOTAL EQUITY AND LIABILITIES	1,549.05	1,661.68



TRIOCHEM PRODUCTS LIMITED

MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS

Registered Office: 4th Floor, Sambava Chambers, Sir. P. M. Road, Fort, Mumbai, Maharashtra,

PIN: 400001. Telephone: 00 91 (22) 2266 3150 Fax: 00 91 (22) 2202 4657

E-mail: info@amphray.com Website: www.triochemproducts.com

Corporate Identity Number: L24249MH1972PLC015544



CASH FLOW STATEMENT FOR THE HALF YEAR ENDED 30TH SEPTEMBER, 2020			
	Particulars	Half Year Ended	
		30-Sep-20 (Unaudited)	30-Sep-19 (Unaudited)
A	CASH FLOW FROM OPERATING ACTIVITIES		
	Net Profit before tax and Extraordinary Items	(42.47)	3.45
	Adjustment for:		
	Depreciation / Amortisation	6.88	8.36
	Interest Income	(0.59)	(0.32)
	Reclassification of remeasurement of employee benefits	(0.95)	(0.29)
	Interest Expenses	7.06	7.83
	Net loss on sale of Investment	0.06	-
	Investment Expenses	0.03	0.04
	Sundry balance Off	0.00	-
	Operating Profit before Working Capital Changes	(29.99)	19.07
	Adjustments for Working Capital Changes		
	Increase/Decrease in Assets	(60.83)	(424.77)
	Changes in Inventories	(1,012.83)	202.55
	Increase/Decrease Trade Receivable	1,224.60	333.01
	Increase/Decrease in other financial and non-financial assets	(0.00)	-
	Increase/Decrease Trade payables	(37.79)	(13.48)
	Increase/Decrease in other financial and non-financial liabilities	(7.60)	3.68
	Increase/Decrease in Liabilities	(76.18)	3.74
	Changes in Provision	0.63	0.34
	Cash Generated from Operations	0.01	124.14
	Direct taxes paid / (refund)	(14.50)	(21.51)
	Net Cash from Operating Activities	(14.49)	102.63
B	CASH FLOW FROM INVESTING ACTIVITIES		
	Purchase of Fixed Assets including Capital Work in Progress	-	-
	(Loss) on Sale of Investment	(0.06)	-
	Investment Expenses	(0.03)	(0.04)
	Interest Received	0.60	0.54
	Net Cash Used in Investing Activity	0.51	0.50
	CASH FLOW FROM FINANCING ACTIVITIES		
	Net (Decrease)/ Increase in Short Term Borrowings	50.27	(39.14)
	Interest Paid	(7.06)	(7.83)
	Net Cash Used in Financing Activity	43.21	(46.97)
	NET CHANGES IN CASH & CASH EQUIVALENTS (A+B+C)	29.23	56.16
	OPENING BALANCE OF CASH & CASH EQUIVALENTS	55.31	24.90
	CLOSING BALANCE OF CASH & CASH EQUIVALENTS	84.54	81.06
		(29.23)	(56.16)



Handwritten signature in blue ink.

Handwritten mark 'x' in blue ink.

Handwritten mark '4' in blue ink.

TRIOCHEM PRODUCTS LIMITED

MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS

Registered Office: 4th Floor, Sambava Chambers, Sir. P. M. Road, Fort, Mumbai, Maharashtra,

PIN: 400001. Telephone: 00 91 (22) 2266 3150 Fax: 00 91 (22) 2202 4657

E-mail: info@amphray.com Website: www.triochemproducts.com

Corporate Identity Number: L24249MH1972PLC015544

**Notes:**

- 1) The above unaudited financial results of the Company for the quarter and half year ended September 30, 2020 have been reviewed by the Audit committee of the Board and approved by the Board of Directors at its meeting held on 12.11.2020
- 2) The Audited financial results have been prepared in accordance with Indian Accounting Standards (Ins AS), the provisions of the Companies Act, 2013 (the Act), as applicable and guidelines issued by the Securities and Exchange Board of India (SEBI).
- 3) The Company operates in single segment only, i.e. chemical and pharmaceuticals; therefore, disclosure requirement of Indian Accounting Standard (IND AS-108) "Segment Reporting" is not applicable.
- 4) The outbreak of corona virus (COVID-19) pandemic globally and in India is causing significant disturbance and slowdown of economic activity. The Group's operations and revenue during the quarter were impacted due to COVID-19. The Group has taken into account the possible impact of COVID-19 in preparation of the unaudited consolidated financial results, including its assessment of recoverable value of its assets based on internal and external information upto the date of approval of these unaudited consolidated financial results and current indicators of future economic conditions.
- 5) Operations during the quarter continued to be impacted by measures to contain covid-19 pandemic. The business gathered momentum, though recovery has been gradual and partial. Accordingly, the results for the quarter are not comparable with those for the previous quarter and corresponding quarter of previous year.
- 6) The Indian Parliament has approved the code on Social security, 2020 which would impact the contributions by the company towards provident Fund and Gratuity. The effective date from which the changes are applicable is yet to be notified and the rules for quantifying the financial impact are yet to be framed. In view of this, impact if any, of the change will be assessed and accounted in period of notification of the relevant provisions.
- 7) The Corresponding figures of the previous quarter / year have been regrouped, recasted and reclassified to make them comparable wherever necessary.

FOR TRIOCHEM PRODUCTS LIMITED

RAMU S. DEORA

DIRECTOR & CEO

DIN : 00312369

Place: Mumbai

Dated: 12th November, 2020



Independent Auditor's Review Report on Unaudited Quarterly Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To,

The Board of Directors of TRIOCHEM PRODUCTS LIMITED

1. We have reviewed the accompanying statement of unaudited financial results of **TRIOCHEM PRODUCTS LIMITED ("The Company")** for the quarter and half year ended September 30, 2020 being submitted by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by SEBI from time to time. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
2. We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information performed by Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian Accounting Standards (Ind AS) and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Kanu Doshi Associates LLP
Chartered Accountants
Firm Registration No: 104746W/W100096

KUNAL SUMANT Digitally signed by KUNAL
SUMANT VAKHARIA
VAKHARIA Date: 2020.11.12 15:56:02
+05'30'

Kunal Vakharia
Partner
Membership No.: 148916
UDIN: 20148916AAAAFU2119

Place: Mumbai
Date: 12th November 2020



BSE LTD
ACKNOWLEDGEMENT

Acknowledgement No	: 1211202004140733	Date & Time	: 12/11/2020 16:14:07
Scrip Code	: 512101		
Entity Name	: Triochem Products Limited		
Compliance Type	: Regulation 33 - Financial Results		
Quarter / Period	: 30/09/2020		
Mode	: E-Filing		

General information about company	
Scrip code	512101
NSE Symbol	
MSEI Symbol	
ISIN*	INE331E01013
Name of company	Triochem Products Limited
Type of company	
Class of security	Equity
Date of start of financial year	01-04-2020
Date of end of financial year	31-03-2021
Date of board meeting when results were approved	12-11-2020
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	04-11-2020
Description of presentation currency	INR
Level of rounding used in financial results	Lakhs
Reporting Quarter	Half yearly
Nature of report standalone or consolidated	Standalone
Whether results are audited or unaudited	Unaudited
Segment Reporting	Single segment
Description of single segment	The Company operates in single segment only, i.e. chemical and pharmaceuticals; therefore, disclosure requirement of Indian Accounting Standard (IND AS-108) "Segment Reporting" is not applicable.
Start date and time of board meeting	12-11-2020 14:00
End date and time of board meeting	12-11-2020 15:40
Whether cash flow statement is applicable on company	Yes
Type of cash flow statement	Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification	Not applicable

Financial Results – Ind-AS			
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-07-2020	01-04-2020
B	Date of end of reporting period	30-09-2020	30-09-2020
C	Whether results are audited or unaudited	Unaudited	Unaudited
D	Nature of report standalone or consolidated	Standalone	Standalone
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.		
1	Income		
	Revenue from operations	225.86	225.86
	Other income	4.38	5.68
	Total income	230.24	231.54
2	Expenses		
(a)	Cost of materials consumed	226.06	644.54
(b)	Purchases of stock-in-trade	0	0
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	-47.76	-472.07
(d)	Employee benefit expense	16.89	33.78
(e)	Finance costs	4.97	7.06
(f)	Depreciation, depletion and amortisation expense	3.46	6.88
(f)	Other Expenses		
1	Other Expenditure	33.78	53.82
10			
	Total other expenses	33.78	53.82
	Total expenses	237.4	274.01

Financial Results – Ind-AS			
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-07-2020	01-04-2020
B	Date of end of reporting period	30-09-2020	30-09-2020
C	Whether results are audited or unaudited	Unaudited	Unaudited
D	Nature of report standalone or consolidated	Standalone	Standalone
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.		
3	Total profit before exceptional items and tax	-7.16	-42.47
4	Exceptional items	0	0
5	Total profit before tax	-7.16	-42.47
7	Tax expense		
8	Current tax	0	0.02
9	Deferred tax	-1.73	-10.56
10	Total tax expenses	-1.73	-10.54
11	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0
14	Net Profit Loss for the period from continuing operations	-5.43	-31.93
15	Profit (loss) from discontinued operations before tax	0	0
16	Tax expense of discontinued operations	0	0
17	Net profit (loss) from discontinued operation after tax	0	0
19	Share of profit (loss) of associates and joint ventures accounted for using equity method	0	0
21	Total profit (loss) for period	-5.43	-31.93

Financial Results – Ind-AS			
Particulars		3 months/ 6 month ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-07-2020	01-04-2020
B	Date of end of reporting period	30-09-2020	30-09-2020
C	Whether results are audited or unaudited	Unaudited	Unaudited
D	Nature of report standalone or consolidated	Standalone	Standalone
Other comprehensive income [Abstract]			
1 Amount of items that will not be reclassified to profit and loss			
	Total Amount of items that will not be reclassified to profit and loss		
2	Income tax relating to items that will not be reclassified to profit or loss	0	0
3 Amount of items that will be reclassified to profit and loss			
1	Item that will not be reclassified to profit or loss	-1.06	-0.95
2	Income tax relating to items that will not be reclassified to profit or loss	0.27	0.24
	Total Amount of items that will be reclassified to profit and loss	-0.79	-0.71
4	Income tax relating to items that will be reclassified to profit or loss	0	0
5	Total Other comprehensive income	-0.79	-0.71

Financial Results – Ind-AS			
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-07-2020	01-04-2020
B	Date of end of reporting period	30-09-2020	30-09-2020
C	Whether results are audited or unaudited	Unaudited	Unaudited
D	Nature of report standalone or consolidated	Standalone	Standalone
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.		
23	Total Comprehensive Income for the period	-6.22	-32.64
24	Total profit or loss, attributable to		
	Profit or loss, attributable to owners of parent		
	Total profit or loss, attributable to non-controlling interests		
25	Total Comprehensive income for the period attributable to		
	Comprehensive income for the period attributable to owners of parent	0	0
	Total comprehensive income for the period attributable to owners of parent non-controlling interests	0	0
26	Details of equity share capital		
	Paid-up equity share capital	24.5	24.5
	Face value of equity share capital	10	10
27	Details of debt securities		
28	Reserves excluding revaluation reserve		
29	Earnings per share		
i	Earnings per equity share for continuing operations		
	Basic earnings (loss) per share from continuing operations	-2.22	-13.03
	Diluted earnings (loss) per share from continuing operations	-2.22	-13.03
ii	Earnings per equity share for discontinued operations		
	Basic earnings (loss) per share from discontinued operations	0	0
	Diluted earnings (loss) per share from discontinued operations	0	0
ii	Earnings per equity share		
	Basic earnings (loss) per share from continuing and discontinued operations	-2.22	-13.03
	Diluted earnings (loss) per share from continuing and discontinued operations	-2.22	-13.03
30	Debt equity ratio		
31	Debt service coverage ratio		
32	Interest service coverage ratio		
33	Disclosure of notes on financial results	Textual Information(1)	

Text Block	
Textual Information(1)	<p>1) The above unaudited financial results of the Company for the quarter and half year ended September 30, 2020 have been reviewed by the Audit committee of the Board and approved by the Board of Directors at its meeting held on 12.11.2020</p> <p>2) The Audited financial results have been prepared in accordance with Indian Accounting Standards (Ins AS), the provisions of the Companies Act, 2013 (the Act), as applicable and guidelines issued by the Securities and Exchange Board of India (SEBI).</p> <p>3) The Company operates in single segment only, i.e. chemical and pharmaceuticals; therefore, disclosure requirement of Indian Accounting Standard (IND AS-108) "Segment Reporting" is not applicable.</p> <p>4) The outbreak of corona virus (COVID-19) pandemic globally and in India is causing significant disturbance and slowdown of economic activity. The Group's operations and revenue during the quarter were impacted due to COVID-19. The Group has taken into account the possible impact of COVID-19 in preparation of the unaudited consolidated financial results, including its assessment of recoverable value of its assets based on internal and external information upto the date of approval of these unaudited consolidated financial results and current indicators of future economic conditions</p> <p>5) Operations during the quarter continued to be impacted by measures to contain covid-19 pandemic. The business gathered momentum, though recovery has been gradual and partial. Accordingly, the results for the quarter are not comparable with those for the previous quarter and corresponding quarter of previous year.</p> <p>6) The Indian Parliament has approved the code on Social security, 2020 which would impact the contributions by the company towards provident Fund and Gratuity. The effective date from which the changes are applicable is yet to be notified and the rules for quantifying the financial impact are yet to be framed. In view of this, impact if any, of the change will be assessed and accounted in period of notification of the relevant provisions.</p> <p>7) The Corresponding figures of the previous quarter / year have been regrouped, recasted and reclassified to make them comparable wherever necessary.</p>

Statement of Asset and Liabilities		
Particulars		Half year ended (dd-mm-yyyy)
Date of start of reporting period		01-04-2020
Date of end of reporting period		30-09-2020
Whether results are audited or unaudited		Unaudited
Nature of report standalone or consolidated		Standalone
	Assets	
1	Non-current assets	
	Property, plant and equipment	90.83
	Capital work-in-progress	3.24
	Investment property	7.92
	Goodwill	0
	Other intangible assets	0
	Intangible assets under development	0
	Biological assets other than bearer plants	0
	Investments accounted for using equity method	0
	Non-current financial assets	
	Non-current investments	0
	Trade receivables, non-current	0
	Loans, non-current	0
	Other non-current financial assets	7.32
	Total non-current financial assets	7.32
	Deferred tax assets (net)	1.47
	Other non-current assets	1.36
	Total non-current assets	112.14
2	Current assets	
	Inventories	1168.24
	Current financial asset	
	Current investments	0
	Trade receivables, current	15.29
	Cash and cash equivalents	84.54
	Bank balance other than cash and cash equivalents	0
	Loans, current	0
	Other current financial assets	0.33
	Total current financial assets	100.16
	Current tax assets (net)	22
	Other current assets	146.51
	Total current assets	1436.91

Statement of Asset and Liabilities		
	Particulars	Half year ended (dd-mm-yyyy)
	Date of start of reporting period	01-04-2020
	Date of end of reporting period	30-09-2020
	Whether results are audited or unaudited	Unaudited
	Nature of report standalone or consolidated	Standalone
3	Non-current assets classified as held for sale	0
4	Regulatory deferral account debit balances and related deferred tax Assets	0
	Total assets	1549.05
	Equity and liabilities	
	Equity	
	Equity attributable to owners of parent	
	Equity share capital	24.5
	Other equity	1160.5
	Total equity attributable to owners of parent	1185
	Non controlling interest	
	Total equity	1185
	Liabilities	
	Non-current liabilities	
	Non-current financial liabilities	
	Borrowings, non-current	0
	Trade payables, non-current	
	Other non-current financial liabilities	
	Total non-current financial liabilities	0
	Provisions, non-current	0
	Deferred tax liabilities (net)	
	Deferred government grants, Non-current	
	Other non-current liabilities	
	Total non-current liabilities	0
	Current liabilities	
	Current financial liabilities	
	Borrowings, current	300.57
	Trade payables, current	36.22
	Other current financial liabilities	6.33
	Total current financial liabilities	343.12
	Other current liabilities	3.68
	Provisions, current	9.68
	Current tax liabilities (Net)	7.57
	Deferred government grants, Current	
	Total current liabilities	364.05
3	Liabilities directly associated with assets in disposal group classified as held for sale	0
4	Regulatory deferral account credit balances and related deferred tax liability	0
	Total liabilities	364.05
	Total equity and liabilities	1549.05
	Disclosure of notes on assets and liabilities	

Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results		
Particulars	3 months/ 6 month ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period	01-07-2020	01-04-2020
Date of end of reporting period	30-09-2020	30-09-2020
Whether accounts are audited or unaudited	Unaudited	Unaudited
Nature of report standalone or consolidated	Standalone	Standalone
1 Segment Revenue (Income)		
(net sale/income from each segment should be disclosed)		
Total Segment Revenue		
Less: Inter segment revenue		
Revenue from operations		
2 Segment Result		
Profit (+) / Loss (-) before tax and interest from each segment		
Total Profit before tax		
i. Finance cost		
ii. Other Unallocable Expenditure net off Unallocable income		
Profit before tax		
3 (Segment Asset - Segment Liabilities)		
Segment Asset		
Total Segment Asset		
Un-allocable Assets		
Net Segment Asset		
4 Segment Liabilities		
Segment Liabilities		
Total Segment Liabilities		
Un-allocable Liabilities		
Net Segment Liabilities		
Disclosure of notes on segments		

Cash flow statement, indirect		
Particulars		6 months ended (dd-mm-yyyy)
A	Date of start of reporting period	01-04-2020
B	Date of end of reporting period	30-09-2020
C	Whether results are audited or unaudited	Unaudited
D	Nature of report standalone or consolidated	Standalone
Part I	Blue color marked fields are non-mandatory.	
	Statement of cash flows	
	Cash flows from used in operating activities	
	Profit before tax	-42.47
	Adjustments for reconcile profit (loss)	
	Adjustments for finance costs	7.06
	Adjustments for decrease (increase) in inventories	-1012.83
	Adjustments for decrease (increase) in trade receivables, current	1224.6
	Adjustments for decrease (increase) in trade receivables, non-current	0
	Adjustments for decrease (increase) in other current assets	-60.83
	Adjustments for decrease (increase) in other non-current assets	0
	Adjustments for other financial assets, non-current	0
	Adjustments for other financial assets, current	0
	Adjustments for other bank balances	0
	Adjustments for increase (decrease) in trade payables, current	-37.79
	Adjustments for increase (decrease) in trade payables, non-current	0
	Adjustments for increase (decrease) in other current liabilities	-76.18
	Adjustments for increase (decrease) in other non-current liabilities	-7.6
	Adjustments for depreciation and amortisation expense	6.88
	Adjustments for impairment loss reversal of impairment loss recognised in profit or loss	-0.95
	Adjustments for provisions, current	0.63
	Adjustments for provisions, non-current	0
	Adjustments for other financial liabilities, current	0
	Adjustments for other financial liabilities, non-current	0
	Adjustments for unrealised foreign exchange losses gains	0
	Adjustments for dividend income	0
	Adjustments for interest income	0.59
	Adjustments for share-based payments	0
	Adjustments for fair value losses (gains)	0
	Adjustments for undistributed profits of associates	0
	Other adjustments for which cash effects are investing or financing cash flow	0.08
	Other adjustments to reconcile profit (loss)	0
	Other adjustments for non-cash items	0
	Share of profit and loss from partnership firm or association of persons or limited liability partnerships	0
	Total adjustments for reconcile profit (loss)	42.48
	Net cash flows from (used in) operations	0.01
	Dividends received	0
	Interest paid	0
	Interest received	0.6
	Income taxes paid (refund)	14.5
	Other inflows (outflows) of cash	0
	Net cash flows from (used in) operating activities	-13.89
	Cash flows from used in investing activities	

	Cash flows from losing control of subsidiaries or other businesses	0
	Cash flows used in obtaining control of subsidiaries or other businesses	0
	Other cash receipts from sales of equity or debt instruments of other entities	0
	Other cash payments to acquire equity or debt instruments of other entities	0
	Other cash receipts from sales of interests in joint ventures	0
	Other cash payments to acquire interests in joint ventures	0
	Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships	0
	Cash payment for investment in partnership firm or association of persons or limited liability partnerships	0
	Proceeds from sales of property, plant and equipment	0
	Purchase of property, plant and equipment	0
	Proceeds from sales of investment property	-0.06
	Purchase of investment property	0
	Proceeds from sales of intangible assets	0
	Purchase of intangible assets	0
	Proceeds from sales of intangible assets under development	0
	Purchase of intangible assets under development	0
	Proceeds from sales of goodwill	0
	Purchase of goodwill	0
	Proceeds from biological assets other than bearer plants	0
	Purchase of biological assets other than bearer plants	0
	Proceeds from government grants	0
	Proceeds from sales of other long-term assets	0
	Purchase of other long-term assets	0
	Cash advances and loans made to other parties	0
	Cash receipts from repayment of advances and loans made to other parties	0
	Cash payments for future contracts, forward contracts, option contracts and swap contracts	0
	Cash receipts from future contracts, forward contracts, option contracts and swap contracts	0
	Dividends received	0
	Interest received	0
	Income taxes paid (refund)	0
	Other inflows (outflows) of cash	-0.03
	Net cash flows from (used in) investing activities	-0.09
	Cash flows from used in financing activities	
	Proceeds from changes in ownership interests in subsidiaries	0
	Payments from changes in ownership interests in subsidiaries	0
	Proceeds from issuing shares	0
	Proceeds from issuing other equity instruments	0
	Payments to acquire or redeem entity's shares	0
	Payments of other equity instruments	0
	Proceeds from exercise of stock options	0
	Proceeds from issuing debentures notes bonds etc	0
	Proceeds from borrowings	50.27
	Repayments of borrowings	0
	Payments of finance lease liabilities	0
	Payments of lease liabilities	0
	Dividends paid	0
	Interest paid	7.06
	Income taxes paid (refund)	0
	Other inflows (outflows) of cash	0
	Net cash flows from (used in) financing activities	43.21

	Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes	29.23
	Effect of exchange rate changes on cash and cash equivalents	
	Effect of exchange rate changes on cash and cash equivalents	0
	Net increase (decrease) in cash and cash equivalents	29.23
	Cash and cash equivalents cash flow statement at beginning of period	55.31
	Cash and cash equivalents cash flow statement at end of period	84.54

Date & Time of Download : 12/11/2020 16:25:17

BSE ACKNOWLEDGEMENT

Acknowledgement Number	2285374
Date and Time of Submission	11/12/2020 4:25:04 PM
Scripcode and Company Name	512101 - TRIOCHEM PRODUCTS LTD.
Subject / Compliance Regulation	Submission Of Unaudited Financial Results For The Quarter And Half Year Ended 30Th September 2020
Submitted By	Puran Jaykisan Parmar
Designation	Designated Officer for Filing

Disclaimer : - Contents of filings has not been verified at the time of submission.